EUCTR2004-000232-91-IT
Active, not recruiting
Not Applicable
GvHD prophylaxis with ATG-Fresenius S in allogenic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxies with cyclosporine A and Methotrexate with additional pretransplant ATG-Fresenius S
FRESENIUS BIOTECH GMBH0 sites200 target enrollmentStarted: November 9, 2009Last updated:
DrugsATG-Fresenius (S)
Overview
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- FRESENIUS BIOTECH GMBH
- Enrollment
- 200
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Active, not recruiting
Not Applicable
GvHD prophylaxis with ATG-Fresenius S in allogeneic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with additional pretransplant ATG-FRESENIUS S. - SCT trialAML, ALL, MDS, CMEUCTR2004-000232-91-FIFresenius Biotech GmbH200
Completed
Phase 3
GvHD prophylaxis with ATG-Fresenius S in allogeneic Stem Cell Transplantation from matched unrelated donors:A randomised phase III multicenter trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with additional pretransplant ATG-FRESENIUS SGvHD prophylaxisC95Leukaemia of unspecified cell typeDRKS00000002eovii Biotech GmbH202
Completed
Phase 3
Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)Graft vs Host DiseaseNCT00655343Neovii Biotech202
Completed
Phase 3
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute LeukemiaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaNCT00678275Universitätsklinikum Hamburg-Eppendorf161
Recruiting
Phase 1
Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome and receiving an allogeneic stem cell transplantation with an unrelated matched donor after a reduced intensity conditioning regimeAcute myeloid leukemia (AML), Myelodysplastic syndrome (MDS)MedDRA version: 21.0Level: LLTClassification code: 10000886Term: Acute myeloid leukemia Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10028533Term: Myelodysplastic syndrome Class: 100000004864Therapeutic area: Diseases [C] - Immune System Diseases [C20]CTIS2023-504555-27-00Assistance Publique Hopitaux De Paris324